Concert Pharmaceuticals to Present at Upcoming Oppenheimer Healthcare Conference
LEXINGTON, Mass.--(BUSINESS WIRE)--Mar 12, 2019--Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Oppenheimer 29 th Annual Healthcare Conference on March 19, 2019 at 1:00 p.m. ET in New York, NY.
A live webcast of the presentation may be accessed in the Investors section of the Company’s website at www.concertpharma.com. Please log on to the Concert website approximately 15 minutes prior to the scheduled webcast to ensure adequate time for any software downloads that may be required. A replay of the webcast will be available on Concert’s website for two weeks following the presentation.
Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform® (deuterated chemical entity platform) to create novel medicines designed to treat serious diseases and address unmet patient needs. The Company’s approach starts with previously studied compounds, including approved drugs, in which deuterium substitution has the potential to enhance clinical safety, tolerability or efficacy. Concert’s pipeline of innovative medicines targets autoimmune diseases and central nervous systems (CNS) disorders. For more information please visit www.concertpharma.com or follow us on Twitter at @ConcertPharma or on LinkedIn.
Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.
View source version on businesswire.com:https://www.businesswire.com/news/home/20190312005052/en/
CONTACT: Justine Koenigsberg
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS PHARMACEUTICAL
SOURCE: Concert Pharmaceuticals, Inc.
Copyright Business Wire 2019.
PUB: 03/12/2019 07:00 AM/DISC: 03/12/2019 07:01 AM